Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials
BACKGROUND: The COVID-19 vaccination program, which uses various types of vaccines, has been applied since the beginning of 2021. However, the efficacy in the context of seroconversion rate remains unclear. OBJECTIVE: To assess the seroconversion rates among different COVID-19 vaccines using a netw...
Saved in:
Main Author: | |
---|---|
Format: | Article PeerReviewed |
Language: | English |
Published: |
F1000
2022
|
Subjects: | |
Online Access: | https://repository.ugm.ac.id/283779/1/37b7414f-937f-423d-bf44-122cb83a3ff0_110281_-_jonny_fajar.pdf https://repository.ugm.ac.id/283779/ https://f1000research.com/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Universitas Gadjah Mada |
Language: | English |
id |
id-ugm-repo.283779 |
---|---|
record_format |
dspace |
spelling |
id-ugm-repo.2837792023-11-22T06:50:58Z https://repository.ugm.ac.id/283779/ Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials Hindom, Maria Humoural Immunology and Immunochemistry Immunology not elsewhere classified BACKGROUND: The COVID-19 vaccination program, which uses various types of vaccines, has been applied since the beginning of 2021. However, the efficacy in the context of seroconversion rate remains unclear. OBJECTIVE: To assess the seroconversion rates among different COVID-19 vaccines using a network meta-analysis approach. METHODS: A network meta-analysis of randomized controlled trials (RCTs) was conducted during the study period. Data of interest, such as seroconversion rate and the type of COVID-19 vaccine, were extracted from each study. The analysis was performed using single-arm analysis by calculating the cumulative seroconversion rate. A network meta-analysis was conducted using the Bayesian method. RESULTS: A total of 31 RCTs were included in our analysis. Our pooled calculation revealed that the seroconversion rates of inactivated messenger ribonucleic acid (mRNA), protein subunit, and vector COVID-19 vaccines during the follow-up periods were 93.2%, 93.9%, 65.3%, and 54.7%, respectively, at ≤ 15 days; 96.0%, 94.8%, 91.2%, and 89.7%, respectively, between days 16–30; and 98.5%, 98.6%, 98.5%, and 96.2%, respectively, between days 31–60.The indirect comparison revealed that in the follow-up periods of ≤ 15 and 16–30 days, the inactivated and mRNA COVID-19 vaccines had superior seroconversion rates compared with those of the protein subunit and vector vaccines. In the follow-up period of 31–60 days, the highest seroconversion rates were found in the inactivated, mRNA, and protein subunit COVID-19 vaccines. CONCLUSION: This study provides valuable information regarding the comparison of seroconversion rates of COVID-19 vaccines. F1000 2022 Article PeerReviewed application/pdf en https://repository.ugm.ac.id/283779/1/37b7414f-937f-423d-bf44-122cb83a3ff0_110281_-_jonny_fajar.pdf Hindom, Maria (2022) Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials. F1000Research, 11 (299). pp. 1-19. https://f1000research.com/ 10.12688/f1000research.110281.1 |
institution |
Universitas Gadjah Mada |
building |
UGM Library |
continent |
Asia |
country |
Indonesia Indonesia |
content_provider |
UGM Library |
collection |
Repository Civitas UGM |
language |
English |
topic |
Humoural Immunology and Immunochemistry Immunology not elsewhere classified |
spellingShingle |
Humoural Immunology and Immunochemistry Immunology not elsewhere classified Hindom, Maria Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials |
description |
BACKGROUND: The COVID-19 vaccination program, which uses various types of vaccines, has been applied since the beginning of 2021. However, the efficacy in the context of seroconversion rate remains unclear.
OBJECTIVE: To assess the seroconversion rates among different COVID-19 vaccines using a network meta-analysis approach.
METHODS: A network meta-analysis of randomized controlled trials (RCTs) was conducted during the study period. Data of interest, such as seroconversion rate and the type of COVID-19 vaccine, were extracted from each study. The analysis was performed using single-arm analysis by calculating the cumulative seroconversion rate. A network meta-analysis was conducted using the Bayesian method.
RESULTS: A total of 31 RCTs were included in our analysis. Our pooled calculation revealed that the seroconversion rates of inactivated messenger ribonucleic acid (mRNA), protein subunit, and vector COVID-19 vaccines during the follow-up periods were 93.2%, 93.9%, 65.3%, and 54.7%, respectively, at ≤ 15 days; 96.0%, 94.8%, 91.2%, and 89.7%, respectively, between days 16–30; and 98.5%, 98.6%, 98.5%, and 96.2%, respectively, between days 31–60.The indirect comparison revealed that in the follow-up periods of ≤ 15 and 16–30 days, the inactivated and mRNA COVID-19 vaccines had superior seroconversion rates compared with those of the protein subunit and vector vaccines. In the follow-up period of 31–60 days, the highest seroconversion rates were found in the inactivated, mRNA, and protein subunit COVID-19 vaccines.
CONCLUSION: This study provides valuable information regarding the comparison of seroconversion rates of COVID-19 vaccines. |
format |
Article PeerReviewed |
author |
Hindom, Maria |
author_facet |
Hindom, Maria |
author_sort |
Hindom, Maria |
title |
Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials |
title_short |
Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials |
title_full |
Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials |
title_fullStr |
Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials |
title_full_unstemmed |
Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials |
title_sort |
seroconversion rates among different designs of covid-19 vaccines: a network meta-analysis of randomized controlled trials |
publisher |
F1000 |
publishDate |
2022 |
url |
https://repository.ugm.ac.id/283779/1/37b7414f-937f-423d-bf44-122cb83a3ff0_110281_-_jonny_fajar.pdf https://repository.ugm.ac.id/283779/ https://f1000research.com/ |
_version_ |
1783956497011572736 |